Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information visit About Merckįor over a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. is a member of the Canadian Biosimilars Forum, an alliance of companies who represent the breadth of the biosimilars industry and that are collectively working to increase awareness, access and adoption of biosimilars across Canada. Merck offers a comprehensive patient assistance program for RENFLEXIS™ to eligible patients through its Merck HARMONY® patient assistance program.įor more information about RENFLEXIS™, including the full product indications and clinical data highlights, please consult the product monograph at: įor more information about Merck Biosimilars, visit Merck Canada Inc. 5 About 300,000 Canadian adults (one in every 100) have RA.6 While it can affect any person at any age, women are affected two to three times more frequently than men. 5 Its most common forms include rheumatoid arthritis (RA), psoriatic arthritis (PA) and ankylosing spondylitis (AS). Inflammatory arthritis affects Canadians at every stage of life, irrespective of gender or ethnicity. 4 The burden of these conditions on patients is significant, with quality of life substantially affected. 2 Since 1995, Crohn's disease in Canada has almost doubled in children under the age of 10. 2 Canada also has amongst the highest rates of childhood-onset IBD in the world 3 with approximately 5,900 children living with the disease. "We're committed to continuing to work with provinces and territories throughout Canada to ensure broader access for all patients to the care they need."įor more information on the RENFLEXIS™ public listing, please consult:Ībout inflammatory bowel diseases and inflammatory arthritisĪround 129,000 Canadians live with Crohn's disease and 104,000 with ulcerative colitis, the two main forms of Inflammatory Bowel Disease (IBD). "We are pleased to see the government of British Columbia add Renflexis to its formulary, which offers effective and more affordable treatment options for patients impacted by these diseases," said Manon Lafontaine, Vice-President, Patient Access, Merck Canada. RENFLEXIS™ (infliximab for injection) is approved for the treatment of Crohn's disease and ulcerative colitis in adult and pediatric patients, as well as fistulising Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis in adults. Kirkland, QC /CNW/ - Merck Canada Inc., known as MSD outside Canada and the United States, today announced that the province of British Columbia will now reimburse RENFLEXIS™ (infliximab for injection) under its public drug plan effective August 21, 2018. RENFLEXIS™ has been added to drug formulary for the treatment of adult and pediatric Crohn's disease and ulcerative colitis, as well as for the treatment of fistulising Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |